Key Counseling Points for Valacyclovir Treatment

General Counseling Points

The Centers for Disease Control and Prevention recommends that patients be counseled that valacyclovir is not a cure for herpes infections but can effectively manage symptoms, reduce recurrences, and decrease transmission risk when used appropriately 1
Patients should be advised to complete the full course of treatment even if symptoms improve before completion 1

For episodic treatment, the Centers for Disease Control and Prevention stresses the importance of starting medication at the earliest symptoms (prodrome: tingling, itching, or burning) 1

The Centers for Disease Control and Prevention informs patients that genital herpes is a sexually transmitted disease and they should avoid sexual contact when lesions or symptoms are present 1
The Centers for Disease Control and Prevention explains that asymptomatic viral shedding can occur even during suppressive therapy, so safer sex practices should still be used 1
For recurrent episodes, treatment should be initiated within 24 hours of symptom onset for maximum effectiveness 1

The Centers for Disease Control and Prevention recommends that higher doses may be required for immunocompromised patients (e.g., HIV-infected individuals) 1, 2
The Centers for Disease Control and Prevention explains that treatment should continue until clinical resolution is attained 2
The Centers for Disease Control and Prevention notes that persistent lesions despite treatment may indicate resistance, requiring alternative therapy 2

The Centers for Disease Control and Prevention informs women of childbearing age about the registry that monitors pregnancy outcomes in women exposed to valacyclovir 2, 3
The Centers for Disease Control and Prevention reports that current registry findings do not indicate increased risk for major birth defects with acyclovir treatment 2

The Centers for Disease Control and Prevention recommends that for patients on suppressive therapy, discuss discontinuation after 1 year to assess recurrence frequency, as recurrences often decrease over time 1, 4
The Centers for Disease Control and Prevention explains that safety has been documented for up to 1 year with valacyclovir for suppressive therapy 1, 4

The Centers for Disease Control and Prevention notes that very high doses (8g/day) in immunocompromised patients have been associated with serious adverse events, but recommended therapeutic doses are considered safe 2